PDCD1 and neoplasm: For anti-PD-1 and anti-PD-L1 antibodies, the expression of PD-L1 in tumor sections was initially a reasonable biomarker, and the accompanied testing kit of PD-L1 expression was indispensable for approval of an anti-PD-1/PD-L1 antibody by US FDA.